RC
BCYC

Rangeley Capital’s Bicycle Therapeutics BCYC Stock Holding History

Rangeley Capital’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Buy
232,260
+100,260
+76% +$573K 1.05% 31
2025
Q4 		$935K Buy
132,000
+2,000
+2% +$14.7K 0.78% 39
2025
Q3 		$1.01M Buy
130,000
+55,000
+73% +$415K 0.87% 30
2025
Q2 		$521K Buy
+75,000
New +$597K 0.62% 35

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rangeley Capital's BCYC Position: Q1 2026 in Review

Rangeley Capital increased its Bicycle Therapeutics (BCYC) stake by 76% in Q1 2026, buying an estimated $573K and bringing the position to 232,260 shares worth $1.08M. The position accounts for 1.05% of the portfolio, ranked #31.

Rangeley Capital first reported a position in BCYC in Q2 2025 and has held it in 4 quarters since. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Rangeley Capital held 232,260 shares of Bicycle Therapeutics worth $1.08M as of Q1 2026.
  • Rangeley Capital bought 100,260 Bicycle Therapeutics shares in Q1 2026, an estimated $573K.
  • Bicycle Therapeutics made up 1.05% of Rangeley Capital's portfolio in Q1 2026, its #31 holding.
  • Rangeley Capital first reported a position in Bicycle Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.